PYC Therapeutics Limited (ASX:PYC)
Australia · Delayed Price · Currency is AUD | Market Cap | 2.21B +212.3% |
| Revenue (ttm) | 25.99M +10.6% |
| Net Income | -43.34M |
| EPS | -0.06 |
| Shares Out | 983.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,866,025 |
| Open | 2.250 |
| Previous Close | 2.245 |
| Day's Range | 2.200 - 2.400 |
| 52-Week Range | 0.847 - 2.620 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 3.94 (+64.17%) |
| Earnings Date | Nov 23, 2026 |
About PYC Therapeutics
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. ... [Read more]
Financial Performance
In fiscal year 2026, PYC Therapeutics's revenue was 25.99 million, an increase of 10.64% compared to the previous year's 23.49 million. Losses were -43.34 million, -13.84% less than in 2025.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PYC stock is "Strong Buy." The 12-month stock price target is $3.94, which is an increase of 64.17% from the latest price.
News
PYC Therapeutics Earnings Call Transcript: Q3 2026
Upcoming 18 months will see multiple human safety and efficacy readouts across four clinical programs, with the PKD program nearing a pivotal transition to registrational studies. Clean safety data, organizational expansion, and strong funding position the company for late-stage development and potential dual listing.
PYC Therapeutics Slides: Q3 2026
PYC Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on September 3, 2026.
PYC Therapeutics Annual report: H2 2026
PYC Therapeutics has published its H2 2026 annual report on August 27, 2026.
PYC Therapeutics Slides: Investor presentation
PYC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 19, 2026.
PYC Therapeutics Transcript: AGM 2026
The meeting approved all resolutions, including a new Rights Plan, increased director remuneration, and CEO options, with strong shareholder support. Strategic focus is on advancing clinical programs, expanding the board and executive team, and maintaining robust governance. Key milestones in clinical development are expected soon.
PYC Therapeutics Transcript: Investor update
Significant progress has been made across the clinical pipeline, with key data readouts for PKD, PMS, and ophthalmology programs expected over the next 18–24 months. The company is prioritizing execution, expanding its board, and deepening U.S. market engagement to maximize value from upcoming milestones.
PYC Therapeutics Slides: Investor update
PYC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
PYC Therapeutics Quarterly report: H1 2026
PYC Therapeutics has published its H1 2026 quarterly earnings report on February 22, 2026.
PYC Therapeutics Slides: Investor presentation
PYC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 1, 2026.
PYC Therapeutics Transcript: AGM 2025
The meeting featured board renewal, strong support for resolutions, and a strategic focus on advancing four rare disease drug programs, with key clinical milestones and commercial opportunities expected over the next 24 months. Funding is secured through 2028, and leadership is committed to long-term growth.
PYC Therapeutics Slides: FY 2025
PYC Therapeutics has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 17, 2025.
PYC Therapeutics Earnings Call Transcript: Q1 2026
Recent financing has secured over $750 million in cash runway, enabling advancement of four decorrelated pipeline assets through key clinical milestones. Regulatory and clinical variability may affect timelines, but strong investor alignment and strategic focus support long-term growth.
PYC Therapeutics Slides: Q1 2026
PYC Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on October 26, 2025.
PYC Therapeutics Earnings release: Q1 2026
PYC Therapeutics released its Q1 2026 earnings on October 26, 2025, summarizing the period's financial results.
PYC Therapeutics Transcript: Investor Update
Board and management changes address past strategic misalignments, with a renewed focus on advancing all four clinical programs and strengthening commercial capabilities. Key milestones across the pipeline are expected over the next 24 months, aiming to close the gap between intrinsic value and market capitalization.
PYC Therapeutics Slides: Investor Update
PYC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2025.